Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
IMUC's Cash-to-Debt is ranked higher than
88% of the 983 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. IMUC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
IMUC' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: -19.38
Beneish M-Score: 6.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -238.76
IMUC's ROE % is ranked lower than
91% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. IMUC: -238.76 )
Ranked among companies with meaningful ROE % only.
IMUC' s ROE % Range Over the Past 10 Years
Min: -480.22  Med: -120.17 Max: -35.53
Current: -238.76
-480.22
-35.53
ROA % -119.03
IMUC's ROA % is ranked lower than
89% of the 992 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. IMUC: -119.03 )
Ranked among companies with meaningful ROA % only.
IMUC' s ROA % Range Over the Past 10 Years
Min: -179.88  Med: -88.12 Max: -31.45
Current: -119.03
-179.88
-31.45
ROC (Joel Greenblatt) % -7285.41
IMUC's ROC (Joel Greenblatt) % is ranked lower than
84% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: -369.38 vs. IMUC: -7285.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IMUC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -79400  Med: -16598.23 Max: 13323.94
Current: -7285.41
-79400
13323.94
3-Year EPS without NRI Growth Rate 7.20
IMUC's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 553 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. IMUC: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IMUC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.1  Med: -4.4 Max: 81.7
Current: 7.2
-28.1
81.7
GuruFocus has detected 2 Warning Signs with ImmunoCellular Therapeutics Ltd $IMUC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IMUC's 30-Y Financials

Financials (Next Earnings Date: 2017-08-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:OTCPK:CBBT, OTCPK:GOVX, OTCPK:LCAR, OTCPK:ICOTF, OTCPK:CRXM, OTCPK:BTHE, OTCPK:TIKRF, OTCPK:GRSO, OTCPK:CLYXF, OTCPK:BIEI, OTCPK:ARNI, OTCPK:HDVY, OTCPK:CAPS, OTCPK:CTTC, OTCPK:PPCB, OTCPK:MDFZF, OTCPK:ADYNF, OTCPK:ENTB, OTCPK:ERGO, OTCPK:GNBT » details
Traded in other countries:KOL1.Germany,
Headquarter Location:USA
ImmunoCellular Therapeutics Ltd is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.

ImmunoCellular Therapeutics Ltd.

Top Ranked Articles about ImmunoCellular Therapeutics Ltd

ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd. - IMUC
ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 15, 2017
ImmunoCellular Therapeutics Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at ASCO 2017
IMUC ALERT: Rosen Law Firm Reminds ImmunoCellular Therapeutics, Ltd. of Important Deadline in Class Action – IMUC
SHAREHOLDER ALERT: Monteverde & Associates PC Invites ImmunoCellular Therapeutics, Ltd. Shareholders with Losses To Contact The Firm Immediately - IMUC
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against ImmunoCellular Therapeutics, Ltd. and Reminds Investors with Losses to Contact the Firm
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of ImmunoCellular Therapeutics, Ltd. Shareholders and a Lead Plaintiff Deadline of June 30, 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against ImmunoCellular Therapeutics, Ltd. and Reminds Investors with Losses to Contact the Firm
IMUC INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving ImmunoCellular Therapeutics, Ltd. and a Lead Plaintiff Deadline of June 30, 2017

Ratios

vs
industry
vs
history
PB Ratio 6.34
IMUC's PB Ratio is ranked lower than
68% of the 888 Companies
in the Global Biotechnology industry.

( Industry Median: 3.78 vs. IMUC: 6.34 )
Ranked among companies with meaningful PB Ratio only.
IMUC' s PB Ratio Range Over the Past 10 Years
Min: 0.09  Med: 5.76 Max: 18.01
Current: 6.34
0.09
18.01
EV-to-EBIT 0.11
IMUC's EV-to-EBIT is ranked higher than
99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 22.66 vs. IMUC: 0.11 )
Ranked among companies with meaningful EV-to-EBIT only.
IMUC' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.9  Med: -4.7 Max: 2.2
Current: 0.11
-19.9
2.2
EV-to-EBITDA 0.11
IMUC's EV-to-EBITDA is ranked higher than
99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.28 vs. IMUC: 0.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMUC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.9  Med: -4.7 Max: 2.2
Current: 0.11
-19.9
2.2
Current Ratio 3.31
IMUC's Current Ratio is ranked lower than
57% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. IMUC: 3.31 )
Ranked among companies with meaningful Current Ratio only.
IMUC' s Current Ratio Range Over the Past 10 Years
Min: 2.64  Med: 17.27 Max: 76.13
Current: 3.31
2.64
76.13
Quick Ratio 2.70
IMUC's Quick Ratio is ranked lower than
61% of the 976 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. IMUC: 2.70 )
Ranked among companies with meaningful Quick Ratio only.
IMUC' s Quick Ratio Range Over the Past 10 Years
Min: 2.64  Med: 17.27 Max: 76.13
Current: 2.7
2.64
76.13

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -33.70
IMUC's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. IMUC: -33.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMUC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -51.6  Med: -30.2 Max: -19.3
Current: -33.7
-51.6
-19.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 6.29
IMUC's Price-to-Tangible-Book is ranked lower than
58% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. IMUC: 6.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IMUC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.98  Med: 2.99 Max: 64.63
Current: 6.29
0.98
64.63
Earnings Yield (Greenblatt) % 875.34
IMUC's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.87 vs. IMUC: 875.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMUC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5421.4  Med: -12.75 Max: 3471
Current: 875.34
-5421.4
3471

More Statistics

EPS (TTM) $ -7.41
Beta0.32
Short Percentage of Float12.92%
52-Week Range $0.80 - 10.60
Shares Outstanding (Mil)3.46

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -8.57
EPS without NRI ($) -8.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IMUC

Headlines

Articles On GuruFocus.com
ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Pati Jun 21 2017 
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ImmunoCellu Jun 14 2017 
ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 15, 2017 Jun 12 2017 
ImmunoCellular Therapeutics Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at A Jun 05 2017 
IMUC ALERT: Rosen Law Firm Reminds ImmunoCellular Therapeutics, Ltd. of Important Deadline in Class Jun 02 2017 
SHAREHOLDER ALERT: Monteverde & Associates PC Invites ImmunoCellular Therapeutics, Ltd. Shareholders Jun 01 2017 
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Immu May 25 2017 
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of ImmunoCell May 25 2017 
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Immun May 23 2017 
IMUC INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving I May 23 2017 

More From Other Websites
DEADLINE APPROACHING: Lundin Law PC Announces a Securities Class Action Lawsuit against... Jun 22 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds ImmunoCellular Therapeutics, Ltd. Shareholders of... Jun 22 2017
9-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against ImmunoCellular... Jun 21 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds ImmunoCellular Therapeutics, Ltd. Shareholders of a... Jun 21 2017
ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further... Jun 21 2017
IMUC INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against... Jun 20 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of ImmunoCellular Therapeutics, Ltd. of a... Jun 20 2017
UPCOMING DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against... Jun 19 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ImmunoCellular Therapeutics, Ltd.... Jun 19 2017
UPCOMING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against ImmunoCellular... Jun 16 2017
IMUC SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action... Jun 16 2017
SHAREHOLDER REMINDER: Khang & Khang LLP Announces a Securities Class Action Lawsuit against... Jun 15 2017
Law Offices of Howard G. Smith Reminds ImmunoCellular Therapeutics, Ltd. Investors of Pending... Jun 15 2017
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of ImmunoCellular Therapeutics, Ltd. of a... Jun 15 2017
SHAREHOLDER REMINDER: Lundin Law PC Announces a Securities Class Action Lawsuit against... Jun 14 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against... Jun 14 2017
DEADLINE APPROACHING: Monteverde & Associates PC Announces a Securities Class Action Lawsuit against... Jun 14 2017
June 30 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit... Jun 14 2017
DEADLINE APPROACHING: Khang & Khang LLP Announces a Securities Class Action Lawsuit against... Jun 13 2017
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of... Jun 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}